These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 35632396)

  • 1. Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination.
    Kiewisz J; Drzyzga D; Rozanska K; Krzynowek E; Lukaszuk K
    Vaccines (Basel); 2022 Apr; 10(5):. PubMed ID: 35632396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination strategy and anti - SARS-CoV-2 S titers in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy).
    Cavalcanti E; Isgrò MA; Rea D; Di Capua L; Trillò G; Russo L; Botti G; Miscio L; Buonaguro FM; Bianchi AAM
    Infect Agent Cancer; 2021 May; 16(1):32. PubMed ID: 33980271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Limited Effect of a History of COVID-19 on Antibody Titers and Adverse Reactions Following BNT162b2 Vaccination: A Single-Center Prospective Study.
    Kushima H; Ishii H; Kinoshita Y; Koide Y; Komiya Y; Kato J; Umehara M; Sakata M; Miyazaki M; Ikuta M
    J Clin Med; 2022 Sep; 11(18):. PubMed ID: 36143040
    [No Abstract]   [Full Text] [Related]  

  • 4. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
    Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
    J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Three Anti-SARS-CoV-2 Serologic Immunoassays for Post-Vaccine Response.
    Di Meo A; Miller JJ; Fabros A; Brinc D; Hall V; Pinzon N; Ierullo M; Ku T; Ferreira VH; Kumar D; Pasic MD; Kulasingam V
    J Appl Lab Med; 2022 Jan; 7(1):57-65. PubMed ID: 34342347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.
    Olariu TR; Ursoniu S; Marincu I; Lupu MA
    Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946275
    [No Abstract]   [Full Text] [Related]  

  • 8. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals.
    Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S
    Front Immunol; 2022; 13():876533. PubMed ID: 35711413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan.
    Kageyama T; Ikeda K; Tanaka S; Taniguchi T; Igari H; Onouchi Y; Kaneda A; Matsushita K; Hanaoka H; Nakada TA; Ohtori S; Yoshino I; Matsubara H; Nakayama T; Yokote K; Nakajima H
    Clin Microbiol Infect; 2021 Dec; 27(12):1861.e1-1861.e5. PubMed ID: 34375755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2.
    Salvaggio M; Fusina F; Albani F; Salvaggio M; Beschi R; Ferrari E; Costa A; Agnoletti L; Facchi E; Natalini G
    J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].
    Özgür D; Tütüncü EE
    Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort.
    Beilhack G; Monteforte R; Frommlet F; Gaggl M; Strassl R; Vychytil A
    Front Immunol; 2021; 12():780594. PubMed ID: 34925359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing SARS-CoV-2 Antibody Responses after Various COVID-19 Vaccinations in Healthcare Workers.
    Kim YK; Minn D; Chang SH; Suh JS
    Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G.
    Hibino M; Watanabe S; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T
    Intern Med; 2022 Mar; 61(6):811-819. PubMed ID: 34980798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody responses induced by the BNT162b2 mRNA COVID-19 vaccine in healthcare workers in a single community hospital in Japan.
    Otsuka S; Hiraoka K; Suzuoki M; Ujiie H; Kato T; Yokota I; Yonezawa K; Oguma K; Iwashiro N; Kato M; Ohara M
    J Infect Chemother; 2022 Apr; 28(4):539-542. PubMed ID: 35016824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
    Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
    Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.